ChromaDex® to Present at 25th Annual ROTH Conference on March 19, 2013
IRVINE, Calif., March 13, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCQB: CDXC) ("ChromaDex"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced today that it will present at the 25th Annual ROTH Conference, which will take place from March 17-20, 2013, at the Ritz-Carlton Laguna Niguel in Dana Point, California. The ChromaDex presentation will be held Tuesday, March 19th at 5:30 p.m. PDT.
A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at http://wsw.com/webcast/roth27/cdxc/ or on ChromaDex's website at http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-calendarpast. An archived replay of the presentation will be available for 90 days.
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 35 percent cyanidin-3-glucoside, NutraGAC™, a Gac fruit powder, pteroberry™, a natural pterostilbene and organic berry blend, and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about ChromaDex, please call 949-600-9694.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Alex Partners, LLC
Scott Wilfong, President
SOURCE ChromaDex Corporation
More by this Source
ChromaDex® Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX®
Jan 06, 2014, 08:30 ET
ChromaDex® Updates Research Activity Agreements For Its NIAGEN™ Nicotinamide Riboside
Nov 22, 2013, 08:30 ET
ChromaDex® Reports Results for the Third Quarter 2013
Nov 21, 2013, 17:50 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.